BMY RSI

What is BMY?

Bristol-Myers Squibb (BMY) has a legacy stretching back to the late 19th century, though the modern powerhouse we know today was formed by the massive 1989 merger of Bristol-Myers and the Squibb Corporation. Since then, it has evolved from a diversified healthcare firm into a specialized biopharmaceutical giant. Its business model centers on high-stakes research and development, targeting complex diseases where it can command premium pricing for life-saving innovations.

The company’s current product lineup is anchored by heavy hitters like the immunotherapy drug Opdivo and the blood thinner Eliquis. However, the 2019 acquisition of Celgene for $74 billion was the real game-changer, bringing in the blockbuster cancer drug Revlimid. While Revlimid is now facing generic competition, BMY has been aggressive in refreshing its pipeline. Its newer portfolio includes drugs like Camzyos for heart disease and Sotyktu for plaque psoriasis, which are critical to the company's future revenue streams and overall growth.

Financially, BMY is a cash flow machine, which is why it is often a favorite for dividend-seeking investors. However, it is currently navigating a tricky transition period. The company has a significant amount of debt from its recent acquisitions, but it maintains a strong investment-grade credit rating. The management team has been proactive and disciplined, recently acquiring Karuna Therapeutics to bolster its neuroscience portfolio, specifically targeting schizophrenia treatments that could provide long-term stability.

Looking toward 2026, the strategic outlook is focused on the new product portfolio hitting its stride and reaching peak commercial potential. By then, BMY expects to have largely offset the revenue losses from older drugs going off-patent through these new launches. The 2026 milestone will be a true test of its R&D productivity as it navigates the impact of the Inflation Reduction Act’s drug price negotiations. Expect BMY to double down on oncology and immunology while trying to prove to the market that its next generation of medicines can match the commercial success of its legendary past hits.

What is RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and magnitude of price changes. Developed by J. Welles Wilder, RSI ranges from 0 to 100 and helps traders identify overbought or oversold conditions in an asset.

For BMY, monitoring the RSI provides valuable insights into potential trend reversals and entry/exit points. When the RSI drops below 30, Bristol-Myers Squibb Co. is typically considered oversold, suggesting the asset may be undervalued. Conversely, an RSI above 70 indicates overbought conditions.

Understanding BMY RSI Signals

• Oversold (RSI below 30): When BMY RSI falls below 30, it suggests the asset may have been sold off excessively and could be due for a bounce. This is often viewed as a potential buying opportunity, though it's important to consider other factors and not rely solely on RSI.
• Overbought (RSI above 70): An RSI above 70 indicates BMY may be overbought, potentially signaling a pullback or consolidation phase. Traders often use this as a signal to take profits or wait for better entry points.
• Divergences: When BMY price makes new highs or lows but RSI doesn't confirm these moves, it can signal weakening momentum and a possible trend reversal.

Daily vs Weekly RSI for BMY

This page displays both daily and weekly RSI for BMY. The daily RSI responds quickly to short-term price movements, making it useful for day traders and swing traders. The weekly RSI provides a broader perspective on momentum trends, helping longer-term investors identify major oversold or overbought conditions.

By analyzing both timeframes together, you can better understand Bristol-Myers Squibb Co.'s momentum at multiple levels and make more informed trading decisions.

Historical RSI Oversold Analysis

Above, we track historical instances when BMY RSI dropped below 30 (oversold territory). Reviewing these past oversold levels helps identify patterns and understand how Bristol-Myers Squibb Co. has historically responded to oversold conditions. Many traders use these historical reference points to gauge potential support levels and timing for entry positions.